Display search results for ** instead (14 products)

Showing 1-10 of 14

This issue of Vital Signs, released on July 31, 2013, discusses perspectives of different Frost & Sullivan analysts on recent noteworthy news items for various markets including Pharma/Biotech, In Vitro Diagnostics, Advanced Medical Technology and Connected Health.

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on July 31, 2013, provides an analysis of sequestration measures that were in effect March 1st, 2013 on academic and government laboratory spending on life science research tools and products. Additionally, a company spotlight is provided for BioScale in Lexington, MA. The company provides a highly innovative pr...

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on August 31, 2013, discusses perspectives of different Frost & Sullivan analysts on recent noteworthy news items for various markets including Pharma/Biotech, Advanced Medical Technology and Connected Health.

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on September 30, 2013, discusses perspectives of different Frost & Sullivan analysts on recent noteworthy news items for various markets including Pharma/Biotech, In Vitro Diagnostics, Advanced Medical Technology and Connected Health.

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on October 31, 2013, discusses perspectives of different Frost & Sullivan analysts on recent noteworthy news items for various markets including Pharma/Biotech, In Vitro Diagnostics, and Advanced Medical Technology.

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on November 22, 2013, provides overview of global IVD market dynamics, discuss growth strategy, and explore early opportunities in the African IVD market. Additionally, a company spotlight is provided for Global BioDiagnostics based in Temple, Texas. The company is focused on developing affordable diagnostic tes...

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on September 30, 2013, provides a market overview and drug pipeline analysis of Type 2 diabetes therapeutics. Additionally, a company spotlight is provided for Trovagene in San Diego, CA. The company has a proprietary transrenal nucleic acid platform with the potential to deliver superior molecular diagnostics i...

USD 450.00

USD 337.50 save 25 %

Given the importance of the changes from PPACA and the creation of the health insurance marketplaces, we are providing our online Frost.com blog on HIX in collected form for the month of September for ease of use by our subscription clients. This discussion is brought to you by our Connected Health research program. Please also follow our blog, par...

USD 450.00

USD 337.50 save 25 %

Given the importance of the changes from PPACA and the creation of the health insurance marketplaces, we are providing our online Frost.com blog on HIX in collected form for the month of August for ease of use by our subscription clients. This discussion is brought to you by our Connected Health research program. Please also follow our blog, part o...

USD 450.00

USD 337.50 save 25 %

Given the importance of the changes from PPACA and the creation of the health insurance marketplaces, we are providing our online Frost.com blog on HIX in collected form for the month of September for ease of use by our subscription clients. This discussion is brought to you by our Connected Health research program. Please also follow our blog, par...

USD 450.00

USD 337.50 save 25 %

Showing 1-10 of 14